The Potential Drug Target and Biomarker, NIHCOLE (Long Intergenic Non-Protein-Coding RNA 2163),

Target Name: NIHCOLE

NCBI ID: G107986389

NIHCOLE

Other Name(s): Long intergenic non-protein coding RNA 2163 | ncRNA involved in NHEJ oncogenic ligation efficiency | LINC02163

The Potential Drug Target and Biomarker, NIHCOLE (Long Intergenic Non-Protein-Coding RNA 2163),

The discovery of long non-protein-coding RNAs (lncRNAs) has revolutionized the understanding of gene regulation in various organisms, including humans. These RNAs have been identified as potential drug targets or biomarkers, due to their involvement in various cellular processes and their ability to regulate gene expression. One such lncRNA is the non-protein-coding RNA (NP-C) 2163, also known as NIHCOLE.

NIHCOLE: A Potential Drug Target and Biomarker

NIHCOLE is a long non-protein-coding RNA that was identified using RNA sequencing (RNA-seq) data. It was found to have high expression levels in various tissues and cells, including the brain, heart, and pancreas, and its expression was significantly correlated with the expression of several protein-coding genes.

The unique feature of NIHCOLE is its long intergenic nature, which means that it spans multiple exons from different genes. This unique property makes it a potential drug target, as drugs can be administered to target specific regions of the genome. Additionally, its non-protein-coding nature makes it a less risky drug target, as the effects of drugs on protein-coding genes are less likely to occur.

NIHCOLE function and potential drug targets

NIHCOLE has been shown to be involved in various cellular processes, including cell growth, differentiation, and metabolism. It has been shown to play a role in the regulation of gene expression, specifically in the regulation of protein-coding genes.

One of the most promising potential drug targets for NIHCOLE is the regulation of cancer cell growth. Cancer cells have a higher expression of NIHCOLE compared to healthy cells, which suggests that it may be a potential drug target for cancer treatment.

Another potential drug target for NIHCOLE is the regulation of metabolism. The levels of NIHCOLE have been shown to be regulated in response to changes in metabolism, such as the levels of glucose and lipids. This suggests that NIHCOLE may be a potential drug target for diseases related to metabolism, such as diabetes.

NIHCOLE as a biomarker

In addition to its potential as a drug target, NIHCOLE has also been shown to be a valuable biomarker for various diseases. For example, it has been shown to be involved in the regulation of insulin sensitivity in obesity, which is a major risk factor for type 2 diabetes.

The identification of NIHCOLE as a potential biomarker for disease has implications for the development of new diagnostic tests and therapies. For example, ifNIHCOLE is found to be involved in the regulation of insulin sensitivity, it may be a potential target for drugs that increase insulin sensitivity in obesity.

Conclusion

NIHCOLE is a long non-protein-coding RNA that has been shown to be involved in various cellular processes and has the potential to be a drug target or biomarker. Its unique property as a long intergenic non-protein-coding RNA makes it a less risky drug target compared to protein-coding genes. Further research is needed to fully understand the functions of NIHCOLE and its potential as a drug target and biomarker.

Protein Name: NcRNA Involved In NHEJ Oncogenic Ligation Efficiency

The "NIHCOLE Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NIHCOLE comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets